[{"id":"1b29cc59-8bde-45f6-9a44-6b0420e8c565","acronym":"","url":"https://clinicaltrials.gov/study/NCT02204098","created_at":"2021-01-18T10:19:08.586Z","updated_at":"2024-07-02T16:35:09.427Z","phase":"Phase 1","brief_title":"Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy","source_id_and_acronym":"NCT02204098","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2 • SCGB2A2","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • SCGB2A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mammaglobin-A DNA vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 01/07/2015","start_date":" 01/07/2015","primary_txt":" Primary completion: 04/06/2022","primary_completion_date":" 04/06/2022","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-04-16"}]